Clinical trial · Observational
GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors
GLUT1: A Novel Tool Reflecting Proliferative Activity of Lung Neuroendocrine Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung neuroendocrine tumor (LNT) represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker. GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT. The team have assessed the GLUT1 immunohistochemical staining in 36 LNT and to assess its diagnostic value.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Tumor | Lung Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunohistochemistry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Assess the GLUT1
- timeFrame
- 5years
- description
- The objective of this study is to assess the GLUT1 staining in cohort of 36 cases of neuroendocrine tumors by immunohistochemistry and to assess its diagnostic interest.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with neuroendocrine tumors Exclusion Criteria: * Patients without neuroendocrine tumors
References
Publications (0)
Data not yet available